A short depression screener for people with tuberculosis

Depression is a common and harmful companion to tuberculosis (TB), and it can worsen treatment outcomes. But finding depression in people with TB is hard because many depressive symptoms — like feeling tired, sleeping poorly, or losing appetite — overlap with the illness itself and side effects of TB medications. To address this challenge, a research team led by corresponding author Paulo Ruíz-Grosso tested whether a short, targeted questionnaire could reliably identify major depressive episodes in patients actively being treated for TB. They started with 58 candidate questions taken from previously validated Spanish-language depression scales and administered them to adults receiving TB treatment in Lima, Peru. Each participant also received a diagnostic interview: a psychiatrist used the SCID-5 to determine whether they had a major depressive episode. The goal was to find a brief set of questions that would distinguish true depressive disorder from the physical symptoms of TB and its treatment, producing a practical screening tool for use in clinics where TB care is delivered.

The study used a cross-sectional validation design with a sample drawn from people on TB treatment in Lima. From the original 58 items, investigators selected questions one by one based on each item’s individual area under the receiver operating characteristic curve (auROC), stopping when adding more items no longer improved discrimination. The psychiatrist-conducted SCID-5 interview served as the diagnostic standard. The final result was an 8-item scale that reached an auROC of 95.9% (95% CI: 92– 99.9%), showing very strong ability to separate those with and without a major depressive episode. At a cutoff score of ≥11 the scale had a sensitivity of 87.2% and a specificity of 92.2%. Internal consistency was good, with Cronbach’s α and McDonald’s ω both equal to 0.804. Notably, questions about anhedonia, energy, sleep, and appetite were excluded from the final set, suggesting the selected items avoided the somatic symptoms that overlap with TB.

The validated 8-item scale demonstrated strong discriminative accuracy and reliability for detecting major depressive episodes among people receiving TB treatment. Because it performed well against the SCID-5 diagnostic interview, the tool could serve as a practical screening instrument in TB clinics, helping clinicians identify patients who need further psychiatric evaluation or mental health support. The exclusion of items on anhedonia, energy, sleep, and appetite indicates the tool may reduce false positives driven by TB-related physical symptoms, focusing instead on aspects of depression that more clearly indicate a major depressive episode in this population. For TB programs, a brief, accurate screener can save time and resources while improving recognition of co-occurring depression, a condition known to affect adherence and outcomes. The study’s findings, reported by Paulo Ruíz-Grosso and colleagues, offer a concise option for routine mental health assessment during TB care in settings like Lima, Peru.